CUSTOMIZED BONE GRAFTS

The "SmartClast" is a startup that develops an innovative technology of personalized bone grafts. SmartClast technology makes the rate of bioresorption of the bone graft adjustable in accordance with the individual characteristics of each patient.

The bone grafts can be supplied in the ready-made form that completely fits the shape and size of the damaged area of the patient's damaged area.

Our technology makes the work of surgeons much more effortless and increases the success rate of osteoplastic operations The use of our technology in osteoplasty reduces the number of postoperative complications and cut the recovery period of patients.

TECHNOLOGY OF CUSTOMIZATION

Precise size and shape

Project SmartClast can produce grafts that fully correspond to the shape and size of the patient's damaged area. This makes the work of the surgeon easier and reduces the time of operation.

In addition to the exact shape and size, the SmartClast's bone grafts have bimodal porosity with gradient porosity between the center to the surface of the bone graft. The surface layer has micropores of optimal configuration, which protect the graft from the germination of soft tissues, and the inner layer has a bimodal porosity, in which the size and direction of the macropores promote faster integration with natural tissue and micropores essential to capture growth factors and other molecules mediating graft remodelling.

Individual specification of material of the bone graft

Most synthetic bone grafts use a composition of HA (hydroxyapatite) and TCP (tricalcium phosphate) in different proportions. But each patient has its own metabolic rate and its own rate of bone remodelling. When the rate of bioresorption of the typical bone graft does not correspond to the patient's rate of bone remodelling, postoperative complications may occur. In some cases, even an additional operation is required.

SmartClast technology is based on the modification of TCP with specially selected biocompatible components. Depending on the natural rate of regeneration of the patient's bone tissue, we adjust the material from which an individual SmartClast bone graft is made to a given bioresorption rate using a chemical modifier. This allows you to synchronize the rate of bioresorption and the rate of formation of new bone tissue. The use of SmartClast technology reduces the risk of postoperative complications and accelerates the remodeling process.

A protocol for planning, configuring, preparing and installing the bone grafts has been developed

The SmartClast project continues to cooperate with the University of Dentistry and Maxillofacial Surgery. Together with leading surgeons of the University, SmartClast analyzed the technological stages of the preparation process for osteoplastic operations using bone grafts produced by the 3B printing method. As a result, a protocol was developed that regulates the sequence of steps for modeling and configuring a bone graft, preparing it for surgery and effective methods of its attachment. This protocol allows CMF surgeons easier plan the operation using ready-to-use 3D grafts and safe time for preparations.

The sample of the bone graft is ready for a test

The SmartClast project produced a bone graft of the damaged area of the jaw. Based on the obtained CT data, we created a digital model of the graft and determined the optimal parameters of bimodal porosity. According to the computed model, a bone graft was made by direct 3D printing. After the heat treatment, the scaffold has the exact size for implantation. An agreement was reached to conduct clinical trials of the SmartClast bone graft with one of the leading Clinics in dental and maxillofacial surgery.

In vivo tests took place in Institute of Bioorganic Chemistry

Comparative tests of "in vivo" bone graft made of SmartClast material were carried out in the Laboratory of Biological Tests of the Institute of Bioorganic Chemistry in Moscow. Tests have confirmed that the osteointegration of the Smartcast graft has a more pronounced character compared to another known type of synthetic graft widely used today in osteoplatics:

"When using the tested drug, the intermediate bone callus by the 30th day had a significantly larger area compared to the intermediate bone callus in cases with the use of a comparison drug. By the 90th day, also in some cases with the use of the tested drug, the intermediate bone callus was represented to a greater extent by mature bone tissue — lamellar."

CURRENT FOCUS

We are working on the development of a technology for adjusting regulated bioresorption to markers that characterize the rate of bone tissue regeneration. We will be glad to have new contacts with experts in this field, it will help us to develop more dynamically.

Evdokimov-center, june22 (6)_edited_edited.jpg

OPPORTUNITIES

We are taking the first steps towards the commercialization of our technology, so we will be glad to have new contacts with partners in the European Union countries (sales, surgeries).